 |
Prospector
Profile
07.1070
|
| |
| Sangui Biotech International, Inc. |
NAICS |
541710 |
| Alfred-Herrhausen-Str. 44
Witten, Germany 58455 |
Description |
Biotechnology |
| 49 (2302) 915-200 |
Employees |
2 |
| http://www.sanguibiotech.com/ |
Revenue |
(mil) |
0.0450 |
| |
Income |
(mil) |
-0.7040 |
| |
Assets |
(mil) |
0.1650 |
| |
Liability |
(mil) |
0.1650 |
| |
(for the year ended 2005-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
HJ & Associates LLC expressed substantial doubt about the ability of Sangui Biotech International, Inc. to continue as a going concern after auditing its financial statements. The auditor pointed to the Company's working capital deficit of $126,750 at June 30, 2005. The Company incurred a net loss of $704,612 and used cash in operating activities of $414,593 for the year ended June 30, 2005.
|
| |
|
Intellectual Property:
The Company seeks patent protection for all of its research and development, and all modifications and improvements thereto. As of June 30, 2005, Sangui GmbH had been granted 18 patents. Furthermore, its subsidiary has applied for 24 patents, most of which have been filed in Germany, the United States, and as an international patent application with the European Patent Office. Four patent applications are related to progress made in the final development stages of the external application of the artificial oxygen carriers. [SEC Filing 10-KSB 06-14-07]
|
| |
|
Description:
The Company is engaged in the development and manufacturing of immunodiagnostic kits, which were sold by SBT in niche markets in the United States and Europe.
|
| |
|
Officers:
Prof. Wolfgang Barnikol, M.D., Ph.D. (Chair, Pres. & CEO); Joachim Fleing, Ph.D. (Dir.); Prof. Joachim Lutz, M.D., Ph.D. (Dir.); Thomas Striepe (Dir.)
|
| |
|
Auditor:
HJ & Associates LLC
|
| |
|
Securities:
Common Stock-Symbol SGBI.PK; Other OTC;
50,000,000 common shares outstanding as of May 29, 2007.
|
| |
| |
| |
| return to main page |
|
|
